Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients

dc.contributor.authorFerrer, Ricard
dc.contributor.authorMateu de Antonio, Francisco Javier
dc.contributor.authorMaseda, Emilio
dc.contributor.authorYébenes, Juan Carlos
dc.contributor.authorAldecoa, César
dc.contributor.authorHaro, Candelaria de
dc.contributor.authorRuiz-Rodríguez, Juan C.
dc.contributor.authorGarnacho Montero, José
dc.date.accessioned2018-11-09T08:30:06Z
dc.date.available2018-11-09T08:30:06Z
dc.date.issued2018
dc.description.abstractEffective resuscitation with human albumin solutions is achieved with less fluid than with crystalloid solutions. However, the role of albumin in today's critical care unit is also linked to its multiple pharmacological effects. Areas covered: The potential clinical benefits of albumin in select populations of critically ill patients like sepsis seem related to immunomodulatory and anti-inflammatory effects, antibiotic transportation and endothelial stabilization. Albumin transports many drugs used in critically ill patients. Such binding to albumin is frequently lessened in critically ill patients with hypoalbuminemia. These changes could result in sub-optimal treatment. Albumin has immunomodulatory capacity by binding several bacterial products. Albumin also influences vascular integrity, contributing to the maintenance of the normal capillary permeability. Moreover, the albumin molecule encompasses several antioxidant properties, thereby significantly reducing re-oxygenation injury, which is especially important in sepsis. In fact, most studies of albumin administration are a combination of a degree of resuscitation with a degree of maintenance or supplementation of albumin. Expert commentary: The potential clinical benefits of the use of albumin in selected critically ill patients such as sepsis seem related to its immunomodulatory and anti-inflammatory effects, antioxidant properties, antibiotic transportation and endothelial stabilization. Additional studies are warranted to further elucidate the underlying physiologic and molecular rationale.
dc.format.mimetypeapplication/pdf
dc.identifier.citationFerrer R, Mateu X, Maseda E, Yébenes JC, Aldecoa C, De Haro C. et al. Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients. Expert Rev Clin Pharmacol. 2018 Feb;11(2):125-137. DOI: 10.1080/17512433.2018.1412827
dc.identifier.doihttp://dx.doi.org/10.1080/17512433.2018.1412827
dc.identifier.issn1751-2433
dc.identifier.urihttp://hdl.handle.net/10230/35723
dc.language.isoeng
dc.publisherTaylor & Francis (Routledge)
dc.relation.ispartofExpert Review of Clinical Pharmacology. 2018 Feb;11(2):125-37
dc.rights© Taylor & Francis. This is an electronic version of an article published in Ferrer R, Mateu X, Maseda E, Yébenes JC, Aldecoa C, De Haro C. et al. Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients. Expert Rev Clin Pharmacol. 2018 Feb;11(2):125-137. Expert review of clinical pharmacology is available online at: https://www.tandfonline.com/doi/abs/10.1080/17512433.2018.1412827?journalCode=ierj20
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.subject.keywordAlbumin
dc.subject.keywordAntioxidation
dc.subject.keywordCritical care
dc.subject.keywordDrug transportation
dc.subject.keywordEndothelium
dc.subject.keywordImmunomodulation
dc.subject.keywordSepsis
dc.subject.otherAlbúmina
dc.subject.otherAntioxidants
dc.titleNon-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/acceptedVersion

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
ferrer-erf-nono.pdf
Size:
223.8 KB
Format:
Adobe Portable Document Format